WPD Pharmaceuticals and CNS Pharmaceuticals Identify Leading Polish Medical Institutions for Berubicin Phase 2 Clinical Trial [Canadian Business Journal (Canada)]
CNS Pharmaceuticals, Inc. (CNSP)
Company Research
Source: Canadian Business Journal
VANCOUVER, British Columbia, April 30, 2020 (GLOBE NEWSWIRE) —WPD Pharmaceuticals Inc.“Company”“WPD”CNSGBMThe US Phase 2 trial Sponsor will be CNS and the Polish Phase 2 trial Sponsor will be WPD, a Polish corporation founded by Professor Waldemar Priebe, founder of both WPD and CNS. The Company expects to initiate both its Phase 2 US and Polish trial of Berubicin in adults with GBM during the second half of 2020.As previously announced, WPD entered into a sublicense agreement with CNS, which gives WPD commercial rights in selected territories in Europe and Asia to Berubicin. WPD was subsequently awarded a reimbursement grant that was valued at $6 million as at the date the grant was announced from the EU/Polish National Center for the research and development of Berubicin. Proceeds from this grant will be used to support the Company’s upcoming Phase 2 clinical trial of Berubicin in adults with GBM in Poland.Mariusz Olejniczak, CEO of WPD PharmaceuticalsWe are honored to have the lead
Show less
Read more
Impact Snapshot
Event Time:
CNSP
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
CNSP alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
CNSP alerts
High impacting CNS Pharmaceuticals, Inc. news events
Weekly update
A roundup of the hottest topics
CNSP
News
- CNS Pharmaceuticals, Inc. (CNSP) Shareholder/Analyst Call Prepared Remarks Transcript [Seeking Alpha]Seeking Alpha
- CNS Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Corporate Update [Yahoo! Finance]Yahoo! Finance
- CNS Pharmaceuticals (NASDAQ:CNSP) was upgraded by analysts at Maxim Group from a "hold" rating to a "buy" rating. They now have a $20.00 price target on the stock.MarketBeat
CNSP
Sec Filings
- 11/21/25 - Form 8-K
- 11/19/25 - Form 4
- 11/19/25 - Form 4
- CNSP's page on the SEC website